Carboplatin versus cisplatin

Vermorken, Jan B.; Huinink, W.W. ten Bokkel; Eisenhauer, E.; Favalli, G.; Belpomme, D; Conte, P.F.; Kaye, Stan B.

doi:10.1093/annonc/4.suppl_4.s41

Cited by 64 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The response rate of 65% obtained with carboplatin and etoposide in this study--in patients with advanced ovarian cancer--is at the lower range of reported response rates with platinum-based combination chemotherapy. The range of the median survival obtained in advanced disease is usually 20-30 months (7). However, in this study the median survival of 19.5 months is at the lower limit, which reflects the poor effect of this combination.…”

Section: Discussioncontrasting

confidence: 53%

See 1 more Smart Citation

Carboplatin and etoposide as first-line chemotherapy in advanced epithelial ovarian cancer

Edelmann

Peretz²,

Barak³

et al. 1995

Int J Gynecol Cancer

View full text Add to dashboard Cite

Carboplatin and etoposide are chemotherapeutic agents active in ovarian cancer, previously proved to have a synergistic activity in animal models. The objective of this phase II study was to determine the feasibility and the efficacy of the combination of carboplatin and etoposide in previously untreated patients with advanced epithelial ovarian cancer. Carboplatin, 400 mg m-2 day 1, and etoposide, 100 mg m-2 days 1-3 every 4 weeks were administered to 28 patients with advanced stage (III-IV) ovarian cancer and a performance status 0-2 (ECOG scale), as a firstline chemotherapy. Twenty-three patients were evaluable for response; 15 (65%) (95% CI: 45-81%) responded, 10 (43%) (95% CI: 25-63%) with clinical complete response. Pathologic complete response demonstrated during postchemotherapy laparotomy was noted in 5/23 (22%) (95% CI: 9-42%) patients. The median progression-free interval was 8.5 months, and median survival was 19.5 months. Toxicity, mainly hematologic, was severe. Nine (32%) patients experienced at least one episode of leucopenic fever, which consequently led to toxic deaths in two (7%) patients. The relatively low response and survival rates with increased toxicity rate are disappointing.

show abstract

Section: Discussioncontrasting

confidence: 53%

“…The possibility of carboplatin substituting cisplatin in the first line chemotherapy for ovarian cancer is still in debate (7). Two randomized trials of combination chemotherapy comparing carboplatin with cisplatin concluded that the cisplatin containing arm was superior in terms of either progression-free or overall survival (s '9).…”

mentioning

confidence: 99%

Carboplatin and etoposide as first-line chemotherapy in advanced epithelial ovarian cancer

Edelmann

Peretz²,

Barak³

et al. 1995

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…1,2 The paclitaxel and cisplatin combination is associated with vomiting, alopecia, and neuropathy, which are the most common nonhematologic side effects. 1,3 Because carboplatin causes significantly fewer of these side effects, 4,5 it increasingly is being substituted for cisplatin in combination therapy.…”

mentioning

confidence: 99%

Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro

Engblom

Rantanen

Kulmala

et al. 1999

Cancer

View full text Add to dashboard Cite

“…In the setting of potentially curable optimal stage III EOC, there remained some uncertainty regarding the efficacy of platinum analogs compared to cisplatin, and an international consensus conference in 1993 recommended against the routine substitution of carboplatin for cisplatin in that setting ( 4 ) .…”

Section: Gog158 Designmentioning

confidence: 99%

Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5

Bookman

Greer

Ozols

2003

Int J Gynecol Cancer

View full text Add to dashboard Cite

Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well-tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Cancer InterGroup (GCIG) evaluating the incorporation of newer cytotoxic agents. Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5.

show abstract

Carboplatin versus cisplatin

Cited by 64 publications

References 26 publications

Carboplatin and etoposide as first-line chemotherapy in advanced epithelial ovarian cancer

Carboplatin and etoposide as first-line chemotherapy in advanced epithelial ovarian cancer

Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro

Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5

Contact Info

Product

Resources

About